Stocks
Enveric Biosciences Secures Up to $13.9 Million in Private Placement
Enveric Biosciences announced a private placement expected to raise up to $13.9 million, with $5 million upfront and potential additional proceeds from...
#drug development 2 articles
Stocks
Sanofi’s Lunsekimig Achieves Phase 2 Endpoints in Asthma, CRSwNP Studies
Sanofi's novel bispecific Nanobody VHH, lunsekimig, met primary and key secondary endpoints in its Phase 2 trials for asthma and CRSwNP, the...